China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced receiving a patent award from the United States Patent and Trademark Office (USPTO) for ZSP1241, a home-grown fibroblast growth factor receptor 4 (FGFR4) inhibitor. The patent, titled “Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof,” is described as the program’s core patent.
ZSP1241: Drug Profile and Development
ZSP1241 has demonstrated anti-tumor activities in liver cancer and gastric cancer human tumor cell line xenotransplantation (CDX) and human tumor tissue-derived xenograft (PDX) models. The drug is expected to produce enhanced efficacy when combined with sorafenib. This recognition from the USPTO underscores the innovative nature of ZSP1241 and its potential in oncology.
Global Patent Portfolio
In addition to the US patent, ZSP1241 has previously obtained patents in Japan, Australia, South Korea, and other locations. This global patent portfolio highlights Zhongsheng Pharmaceutical’s commitment to protecting its intellectual property and advancing its drug development programs.
Future Outlook
The receipt of the USPTO patent for ZSP1241 underscores Guangdong Zhongsheng Pharmaceutical’s progress in developing innovative cancer therapies. By securing patents in multiple jurisdictions, Zhongsheng aims to strengthen its market position and support the global development of ZSP1241.-Fineline Info & Tech
